Polyneuron Pharmaceuticals
Latest round
- Series A
Last raised
- Aug 2020
Total raised
- $41M
Investors
- 6
About Polyneuron Pharmaceuticals
Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron Pharmaceuticals AG specializes in developing treatments for autoimmune diseases. The company focuses on therapeutic candidates that address conditions like anti-MAG neuropathy and Guillain-Barré Syndrome.Polyneuron Pharmaceuticals is focused on developing innovative therapeutic solutions for antibody-mediated autoimmune diseases using its proprietary Antibody-Catch™ technology platform. Its core product offerings include PN-1007 (PPSGG), which targets IgM autoantibodies associated with anti-MAG neuropathy, and PN-1018, designed for Guillain-Barré Syndrome (GBS) and Multifocal Motor Neuropathy (MMN). These injectable glycopolymers act as decoys to selectively bind and eliminate pathogenic autoantibodies while preserving the normal immune response, thereby addressing severe autoimmune conditions that currently lack effective treatments. Polyneuron’s pipeline also includes PN-032 and PN-056, aimed at the selective depletion of isoagglutinin antibodies for ABO-incompatible organ and stem cell transplantation.Polyneuron Pharmaceuticals operates within the biopharmaceutical industry, primarily generating revenue through the development and commercialization of its therapeutic candidates.5 million to date, which supports its ongoing research and clinical trials. Business transactions typically involve partnerships with healthcare providers, biopharma companies, and research institutions, focusing on B2B collaborations for clinical development and distribution of its products. The company’s flagship offerings, such as PN-1007 and PN-1018, are positioned to enter various stages of clinical trials and subsequent market release, with pricing determined through agreements with healthcare systems and potential reimbursement strategies. The company is actively working on launching new products and expanding its presence in European and North American markets to address unmet medical needs in autoimmune therapeutics.
Who invested in Polyneuron Pharmaceuticals
6 investors across 4 rounds
See all investors in Polyneuron Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Polyneuron Pharmaceuticals
Who invested in Polyneuron Pharmaceuticals?
Polyneuron Pharmaceuticals has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Polyneuron Pharmaceuticals raised?
Polyneuron Pharmaceuticals has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Polyneuron Pharmaceuticals last raise money?
Polyneuron Pharmaceuticals's most recent round on record is a Series A, in Aug 2020.
What does Polyneuron Pharmaceuticals do?
Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron Pharmaceuticals AG specializes in developing treatments for autoimmune diseases.
Where is Polyneuron Pharmaceuticals headquartered?
Polyneuron Pharmaceuticals is headquartered in Basel, Switzerland.
Which VCs invest in companies like Polyneuron Pharmaceuticals?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at Polyneuron Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Polyneuron Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.